SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.70), $0.06 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $8.65 million versus the consensus estimate of $8.75 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Western Digital (WDC) June 26 weekly options active, share price down 8.8% into Micron (MU) quarter results
• Bank First National Corp. (BFC) appoints three new directors to board